Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury

线粒体基质金属蛋白酶-2 与心脏损伤

• 批准号: 7797295
• 负责人: DAVID H LOVETT
• 金额: --
• 依托单位: VETERANS AFFAIRS MED CTR SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-10-01 至 2013-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7797295
• 关键词: Adenine Nucleotide Translocase; Age; Amino Acids; Apoptosis; Apoptotic; Area; Bioenergetics; Calcium; Cardiac; Cardiac Myocytes; Cardiovascular Diseases; Cause of Death; Cells; Characteristics; Clinical; Complex; Congestive Heart Failure; Data; Defect; Disease; Enzymes; Evaluation; Event; Evolution; Exhibits; Failure; Functional disorder; Gelatinase A; Gene Expression; Gene Family; Genes; Heart; Heart Diseases; Heart Injuries; Heart Ventricle; Hypertrophy; Immune response; Immune system; In Vitro; Infiltration; Inflammation; Inflammatory; Injury; Ischemia; Ischemic Preconditioning; Lead; Length; Location; Matrix Metalloproteinases; Medical center; Metalloproteinase Gene; Mitochondria; Mitochondrial Matrix; Modeling; Morbidity - disease rate; Mus; Myocardial; Myocardial Infarction; N-terminal; NF-kappa B; Natural Immunity; Nuclear; Oxidation-Reduction; Pattern; Peptide Signal Sequences; Phenotype; Population; Preparation; Process; Protein Isoforms; Proteins; Pump; Reperfusion Injury; Reperfusion Therapy; Respiratory Chain; Role; Signal Transduction; Site; Stress; Structure; Testing; Therapeutic Intervention; Transcript; Transfection; Transgenic Mice; Transgenic Organisms; Variant; Ventricular; Ventricular Remodeling; Veterans; Viral; Work; atherogenesis; base; biological adaptation to stress; chemokine; conditioning; extracellular; in vivo; insight; interest; member; mortality; nuclear factors of activated T-cells; public health relevance; response; ventricular hypertrophy

DESCRIPTION (provided by applicant): Mitochondrial Matrix Metalloproteinase-2 and Cardiac Injury Modulation of cardiac structure and function by matrix metalloproteinases (MMP) has become an area of intense interest. Much effort has been focused on the activity of a specific MMP, (MMP-2), in models of cardiac injury and in the settings of myocardial infarction or congestive heart failure. Clinically, MMP-2 directly contributes to progressive ventricular remodeling and congestive heart failure and a further understanding of the role(s) of this enzyme is critically important. In this Proposal we provide evidence for a previously unrecognized intracellular isoform of MMP-2 (mito-MMP-2) that specifically targets mitochondria. Mito-MMP-2 induces mitochondria-to-nuclear stress signaling, with activation of NF-:B and Nuclear Factor of Activated T-cell (NFAT) signaling cascades. Genes induced by these signaling cascades are critical components of the innate immune system and include pro-inflammatory chemokines and pro-apoptotic factors which lead to cardiomyocyte apoptosis and inflammatory cell infiltration. Transgenic mice expressing mito-MMP-2 exhibit progressive ventricular hypertrophy, severe contractile defects and enhanced injury following ex vivo ischemia/reperfusion injury. We propose to perform a quantitative analysis of the cardiac pathophysiology of the mito-MMP-2 transgenic mice and to determine the temporal pattern of activation of innate immunity genes which contribute to cardiomyocyte apoptosis and inflammation. Further, we will determine the mitochondrial proteolytic targets of mito-MMP-2 and assess the effects of this enzyme on cardiac mitochondrial bioenergetics and ventricular contractile function. These studies will hopefully provide new insights into the pathophysiology of progressive ventricular failure and possibly present new opportunities for therapeutic intervention for this common and severely disabling disorder. PUBLIC HEALTH RELEVANCE: Cardiovascular disease is most common cause of death in veterans treated by the Department of Veterans Affairs Medical Centers. In addition, congestive heart failure caused by defects in the pumping ability of the heart ventricles is a leading contributor to morbidity and mortality in the veteran population. Our work suggests that a new molecule contributes to heart injury and offers the possibility of new forms of therapy for this common and disabling disorder.

描述（由申请人提供）： 线粒体基质金属蛋白酶-2与心脏损伤基质金属蛋白酶（MMP）对心脏结构和功能的调节已成为人们密切关注的领域。许多努力集中在特定MMP（MMP-2）在心脏损伤模型中以及在心肌梗塞或充血性心力衰竭的情况下的活性上。在临床上，MMP-2直接导致进行性心室重构和充血性心力衰竭，进一步了解这种酶的作用至关重要。 在这个提议中，我们提供了以前未被识别的细胞内MMP-2亚型（mito-MMP-2）特异性靶向线粒体的证据。Mito-MMP-2通过NF-：B和活化T细胞核因子（NFAT）信号级联的活化诱导细胞核-至-核应激信号传导。由这些信号级联诱导的基因是先天免疫系统的关键组分，并且包括导致心肌细胞凋亡和炎性细胞浸润的促炎性趋化因子和促凋亡因子。表达mito-MMP-2的转基因小鼠在离体缺血/再灌注损伤后表现出进行性心室肥大、严重的收缩缺陷和增强的损伤。我们建议对mito-MMP-2转基因小鼠的心脏病理生理进行定量分析，并确定导致心肌细胞凋亡和炎症的先天免疫基因激活的时间模式。此外，我们将确定线粒体MMP-2的线粒体蛋白水解靶点，并评估这种酶对心脏线粒体生物能量学和心室收缩功能的影响。这些研究有望为进行性心力衰竭的病理生理学提供新的见解，并可能为这种常见的严重致残性疾病的治疗干预提供新的机会。 公共卫生相关性： 心血管疾病是退伍军人事务部医疗中心治疗的退伍军人最常见的死亡原因。此外，由心室泵送能力缺陷引起的充血性心力衰竭是退伍军人群体发病率和死亡率的主要原因。我们的工作表明，一种新的分子有助于心脏损伤，并为这种常见的致残性疾病提供了新的治疗形式。